Physician profile
Kari Beth Coll
NPI 1538766621
$2,308.73
in general payments reported to CMS, 2019-2025
12 companies · $28.56 in 2025
The $28.56 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $427 · 2022: $338 · 2023: $1,063 · 2024: $452 · 2025: $28.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,543.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,543.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $692.20 | 2021-2024 | |
| Abbvie INC. | $636.25 | 2021-2025 | |
| Viiv Healthcare Company | $494.58 | 2022-2024 | Apretude, Dovato, Cabenuva |
| Theratechnologies INC. | $149.79 | 2021-2022 | |
| Janssen Biotech, INC. | $91.23 | 2021-2023 | Symtuza |
| Janssen Products, LP | $65.00 | 2021 | |
| Merck Sharp & Dohme LLC | $50.40 | 2021-2023 | Delstrigo, Pifeltro |
| Braeburn INC. | $36.83 | 2023-2024 | Brixadi |
| Hologic Sales and Service, LLC | $29.66 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $21.79 | 2023 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.87 | 2021 | |
| Lundbeck LLC | $20.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kari Coll listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.